merck & co. inc. (MRK:New York)
Adel A. F. Mahmoud M.D., Ph.D.
Member of Scientific Advisory Board, Genocea Biosciences, Inc.
|Age||Total Calculated Compensation||This person is connected to 102 board members in 7 different organizations across 7 different industries.|
See Board Relationships
Prof. Adel A. F. Mahmoud, M.D., Ph.D., has been a Professor at Princeton University in the Department of Molecular Biology and the Woodrow Wilson School of Public and International Affairs since 2007. Dr. Mahmoud served as the Chief Medical Advisor, Vaccines and Infectious Diseases of Merck & Co., Inc. since September 1, 2005 until 2006. He served as the President of Merck Vaccines, a subsidiary of Merck & Co. Inc. from May 1999 to 2005. Prior to November 1998, Dr. Mahmoud ...
One Merck DrivePhone: 908-423-1000
Whitehouse Station, New Jersey 08889
Board Members Memberships*
Former Independent Director, Member of Science, Innovation & Technology Committee and Member of Corporate Governance & Nominating Committee
Former Director and Member of Nominating & Corporate Governance Committee
Director, Member of Nomination & Corporate Governance Committee and Member of Compensation Committee
London School Of Hygiene And Tropical Medicine
Faculty of Medicine, University of Ain Shams
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Douglas J. Swirsky CPA, CFA||Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Corporate Secretary and Director|
|Vijay B. Samant||Chief Executive Officer, President, Acting Chief Financial Officer and Director|
|Mark R. Baker J.D.||Chief Executive Officer, Director and Member of Science & Strategy Committee|
Progenics Pharmaceuticals, Inc.
|Daniel J. O’Connor Esq.||Chief Executive Officer, President and Director|
|Jonathan J. Lewis M.D., Ph.D.||Chief Executive Officer and Director|
ZIOPHARM Oncology, Inc.
|$600.0K||Compensation as of Fiscal Year 2013.|